Related Experiment Video
Updated: Apr 7, 2026

05:14
Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran
Published on: November 18, 2022
13.3K
Short-term effects of Poly(I:C) on gut permeability
Valentina Moyano-Porcile1, Loreto Olavarría-Ramírez1, Camila González-Arancibia1
1Grupo de NeuroGastroBioquímica, Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Pharmacological Research
|July 7, 2015
Summary
Poly(I:C), a Toll-like receptor 3 (TLR-3) agonist, alters intestinal barrier function. It decreases colon permeability but increases ileum permeability to small molecules, impacting gut health.
Area of Science:
- Gastroenterology
- Immunology
- Epithelial Biology
Background:
- Intestinal barrier function is crucial for pathogen defense.
- Toll-like receptor 3 (TLR-3) recognizes viral double-stranded RNA.
- The effect of luminal TLR-3 agonists on gut barrier integrity is largely unknown.
Purpose of the Study:
- To investigate the short-term effects of Poly(I:C) on rat ileal and colonic permeability ex vivo.
- To assess the acute impact of intrarectal Poly(I:C) administration on colonic barrier function.
Main Methods:
- Ex vivo incubation of rat ileum and colon with Poly(I:C).
- Measurement of transepithelial electrical resistance (TEER).
- Assessment of macromolecule (dextran) transit across the mucosa.
- In vivo intrarectal administration of Poly(I:C) followed by ex vivo gut sac assays.
Main Results:
- Ileum tissues showed decreased TEER after Poly(I:C) exposure, indicating increased permeability to small molecules.
- Colon tissues exhibited reduced thinning of the mucosal layer and decreased macromolecule transit after Poly(I:C) stimulation.
- In vivo administration of Poly(I:C) led to decreased colonic permeability to macromolecules.
Conclusions:
- Acute Poly(I:C) exposure differentially affects intestinal barrier function, reducing colon permeability while increasing ileum permeability.
- This study is the first to report a direct effect of a TLR-3 ligand on intestinal barrier function.
- Findings suggest region-specific interactions between gut mucosa and microbiota influenced by TLR-3 activation.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Drugs for Treatment of Constipation-Predominant IBS
1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K

